US/Global Blog

Flatiron Health at ASH: Real-world evidence that reveals the why behind hematology treatment decisions

Amy Pierre, Senior Clinical Director — Thu, 05 Nov 2026 02:30:36 GMT

Amy Pierre, MSN, RN, ANP-BC is a nurse practitioner and Senior Clinical Director at Flatiron Health and has spent more than a decade developing research products and caring for patients with multiple myeloma and lymphoma. She sat down to discuss how Flatiron’s real-world evidence is powering high impact research at ASH 2026.

Crossing borders with real-world evidence: lessons from the elacestrant case

Flatiron Health — Thu, 29 Oct 2026 15:49:14 GMT

In oncology, the patients who stand to benefit most from new therapies are often the hardest to study. Niche patient populations defined by specific molecular alterations — like ESR1 mutations in ER+/HER2- advanced or metastatic breast cancer — require real-world data with the clinical depth to actually find them: biomarker test type, test result, mutation status, and the full treatment history that follows.

That level of granularity isn't a given. It requires deeply curated, EHR-derived data that captures both structured and unstructured clinical information across the patient journey. A recent HTA recommendation in the UK — leveraging high-fidelity RWD from Flatiron Health and Foundation Medicine in the United States to build relevant external control arms for elacestrant — offers a compelling case study in how that clinical depth can bridge critical evidence gaps, even across borders.

PCOC 2026 Reflections: Closing the gap between treatment innovation and the point of care

By Alison Fugaro, MMSc, PA-C, Head of Clinical Oncology, Flatiron Health — Tue, 27 Oct 2026 23:02:03 GMT

I recently spent two days at the Patient-Centered Oncology Care (PCOC) conference in Nashville, TN. I left thinking a lot about the distance between breakthrough therapies and the point of care, and how much of our field is now focused on closing that gap.

You could hear it on multiple panels, where leaders from community practices and academic medical centers discussed what it takes to bring CAR-T and bispecific therapies closer to home for patients. And you could hear it in multiple conversations about integrating remote monitoring and symptom management to ensure safety and efficacy as new treatment modalities are adopted.

Oncology practices are building the operational models to deliver increasingly complex therapies to their communities. And there is a groundswell of collaboration behind this, as clinicians, practice leaders, diagnostics companies, academics, payers, and support teams work to accelerate the systems that bring the most cutting-edge options to patients wherever they are treated.

As the pace of innovation accelerates, we need to stay focused on the question of access—who really has access to the newest therapies, clinical trials, and the testing that determines whether a patient is a candidate at all?

That was the center of the panel I joined on Thursday, "Is Precision Medicine Making Cancer Care More or Less Equitable?" moderated by Chris Prakash, MD, Medical Director of Precision Medicine at US Oncology, alongside William Oh, MD, Director of Precision Medicine at Yale Cancer Center; Kyle Kitchen, PharmD, MBA, Chief Clinical Officer at Utah Cancer Specialists; and Lori Brisbin, MS, MLS, SVP of Precision Medicine at Texas Oncology.

Dr. Prakash opened by saying, "This is probably the most exciting topic of the whole conference, right?" I may be biased, but I agree. I’d like to share a few themes that have stayed with me since our discussion.

External control arms for emerging biopharma: building credible comparative evidence

Lockwood Taylor, Head of Regulatory Strategy — Tue, 27 Oct 2026 16:48:13 GMT

Emerging biopharma companies are driving some of today’s most promising advances in oncology, but many face constraints (i.e., ethical, rare populations) that make it difficult to run fully powered randomized controlled trials (RCTs), and are instead relying on single-arm trials to generate evidence. But is a single-arm trial enough to get a new treatment to market?

How AI is expanding what RWD can do for Clinical Development teams

Flatiron Health — Mon, 26 Oct 2026 16:49:38 GMT

The technology around clinical trials is advancing, but teams are facing the same fundamental questions: Who should we recruit? What outcomes can we expect, and how might they vary across patient subgroups? How many patients do we need to recruit? And how can we anticipate and account for inherent differences between trial participants and real-world patients?

From prediction to decision: Digital twins and predictive modeling in clinical development

Flatiron Health — Mon, 26 Oct 2026 16:34:32 GMT

Oncology clinical development leaders face mounting pressure to move faster, often while making critical decisions with limited information. Predictive models and digital twins powered by real-world data (RWD) offer new ways to inform those decisions, helping accelerate timelines and improve probability of success.

Webinar: Building Fit-for-Purpose Oncology Real-World Evidence in Japan

Flatiron Health — Tue, 20 Oct 2026 21:32:57 GMT

Japan is one of the world’s largest oncology markets and an increasingly important part of global real-world evidence (RWE) strategies. Yet oncology RWE in Japan has developed differently than in the US and Europe, shaped by distinct data sources, care delivery models and evolving sponsor needs across clinical development, medical affairs and evidence planning.

Partners in progress: A conversation with Dr. Nathan Littlejohn on OncoEMR® for urology

Flatiron Health — Tue, 13 Oct 2026 19:29:44 GMT

Dr. Nathan Littlejohn is a physician and partner at Triple Crown Urology, part of American Oncology Network (AON). He has been with the practice since it launched three years ago. Today, Triple Crown has six locations across central and southwest Arkansas and provides both general urology and genitourinary (GU) cancer care. It's a busy practice—Dr. Littlejohn sees about 50 patients on a typical day, across visits and procedures.

When Triple Crown became an independent practice and chose to partner with OncoEMR three years ago, they were one of the first urology practices to implement OncoEMR. At first, Dr. Littlejohn wondered how an EHR with deep roots in community oncology would fit a urology practice.

Today, he describes Flatiron as a partner in the practice's success; one that is responsive to the ever-changing needs of the urology landscape, and adaptable to the unique preferences of each practice. Along the way, OncoEMR has given his clinicians time back and made it easier for urology and oncology teams to work together on patients’ care.

Below is an excerpt from our conversation.

Can we trust AI-generated RWD? A systematic validation approach in prostate cancer

Eunice Hankinson, MSN, FNP-C, Clinical Director — Wed, 30 Sep 2026 12:00:00 GMT

The growing use of large language models (LLMs) to extract clinical detail from electronic health records (EHRs) has created new opportunities to generate real-world data (RWD) at scale. For oncology researchers and life sciences decision makers, this unlocks valuable information contained within unstructured data sources, including clinical notes, pathology reports, and other sources that are often difficult to access through traditional abstraction methods. However, as AI-enabled methods are increasingly integrated into evidence generation, questions arise around quality, reliability, and fitness for purpose.

Webinar: An HEOR playbook for oncology RWE and AI use to support European HTA

Flatiron Health — Tue, 08 Sep 2026 19:54:56 GMT

European oncology market access is changing. Since January 2025, new cancer medicines must undergo EU joint clinical assessments alongside EMA review, while national HTA bodies continue to refine evidence requirements across member states. For many submissions, teams rely on real-world data to address comparative effectiveness, heterogeneous PICO needs, and compressed dossier timelines. As demand for faster, higher-quality evidence grows, organizations are also exploring how AI and advanced analytics can support evidence generation and analysis.